DOCSLIB.ORG

Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01 A01A A01AB NATAMYCIN D01AA02 A01AB10 A A01 A01A A01AB NATAMYCIN G01AA02 A01AB10 A A01 A01A A01AB NATAMYCIN S01AA10 A01AB10 A A01 A01A A01AB TETRACYCLINE D06AA04 A01AB13 A A01 A01A A01AB Page 1 vr_meds_ex01_3b_0825s Coding Manual Supplement TETRACYCLINE J01AA07 A01AB13 A A01 A01A A01AB TETRACYCLINE S01AA09 A01AB13 A A01 A01A A01AB TETRACYCLINE S02AA08 A01AB13 A A01 A01A A01AB TETRACYCLINE S03AA02 A01AB13 A A01 A01A A01AB BENZOXONIUM CHLORIDE D08AJ05 A01AB14 A A01 A01A A01AB MEPARTRICIN D01AA06 A01AB16 A A01 A01A A01AB MEPARTRICIN G01AA09 A01AB16 A A01 A01A A01AB MEPARTRICIN G04CX03 A01AB16 A A01 A01A A01AB METRONIDAZOLE D06BX01 A01AB17 A A01 A01A A01AB METRONIDAZOLE G01AF01 A01AB17 A A01 A01A A01AB METRONIDAZOLE J01XD01 A01AB17 A A01 A01A A01AB METRONIDAZOLE P01AB01 A01AB17 A A01 A01A A01AB CLOTRIMAZOLE D01AC01 A01AB18 A A01 A01A A01AB CLOTRIMAZOLE G01AF02 A01AB18 A A01 A01A A01AB CHLORTETRACYCLINE D06AA02 A01AB21 A A01 A01A A01AB CHLORTETRACYCLINE J01AA03 A01AB21 A A01 A01A A01AB CHLORTETRACYCLINE S01AA02 A01AB21 A A01 A01A A01AB DOXYCYCLINE J01AA02 A01AB22 A A01 A01A A01AB MINOCYCLINE J01AA08 A01AB23 A A01 A01A A01AB TRIAMCINOLONE D07AB09 A01AC01 A A01 A01A A01AC TRIAMCINOLONE D07XB02 A01AC01 A A01 A01A A01AC TRIAMCINOLONE H02AB08 A01AC01 A A01 A01A A01AC TRIAMCINOLONE R01AD11 A01AC01 A A01 A01A A01AC TRIAMCINOLONE R03BA06 A01AC01 A A01 A01A A01AC TRIAMCINOLONE S01BA05 A01AC01 A A01 A01A A01AC DEXAMETHASONE C05AA09 A01AC02 A A01 A01A A01AC DEXAMETHASONE D07AB19 A01AC02 A A01 A01A A01AC DEXAMETHASONE D07XB05 A01AC02 A A01 A01A A01AC DEXAMETHASONE D10AA03 A01AC02 A A01 A01A A01AC DEXAMETHASONE H02AB02 A01AC02 A A01 A01A A01AC DEXAMETHASONE R01AD03 A01AC02 A A01 A01A A01AC DEXAMETHASONE S01BA01 A01AC02 A A01 A01A A01AC DEXAMETHASONE S01CB01 A01AC02 A A01 A01A A01AC DEXAMETHASONE S02BA06 A01AC02 A A01 A01A A01AC HYDROCORTISONE A07EA02 A01AC03 A A01 A01A A01AC HYDROCORTISONE C05AA01 A01AC03 A A01 A01A A01AC HYDROCORTISONE D07AA02 A01AC03 A A01 A01A A01AC Page 2 vr_meds_ex01_3b_0825s Coding Manual Supplement HYDROCORTISONE D07XA01 A01AC03 A A01 A01A A01AC HYDROCORTISONE H02AB09 A01AC03 A A01 A01A A01AC HYDROCORTISONE S01BA02 A01AC03 A A01 A01A A01AC HYDROCORTISONE S01CB03 A01AC03 A A01 A01A A01AC HYDROCORTISONE S02BA01 A01AC03 A A01 A01A A01AC PREDNISOLONE , COMBINATIONS R01AD52 A01AC54 A A01 A01A A01AC EPINEPHRINE B02BC09 A01AD01 A A01 A01A A01AD EPINEPHRINE C01CA24 A01AD01 A A01 A01A A01AD EPINEPHRINE R01AA14 A01AD01 A A01 A01A A01AD EPINEPHRINE R03AA01 A01AD01 A A01 A01A A01AD EPINEPHRINE S01EA01 A01AD01 A A01 A01A A01AD BENZYDAMINE G02CC03 A01AD02 A A01 A01A A01AD BENZYDAMINE M01AX07 A01AD02 A A01 A01A A01AD BENZYDAMINE M02AA05 A01AD02 A A01 A01A A01AD ACETYLSALICYLIC ACID B01AC06 A01AD05 A A01 A01A A01AD ACETYLSALICYLIC ACID N02BA01 A01AD05 A A01 A01A A01AD ADRENALONE B02BC05 A01AD06 A A01 A01A A01AD AMLEXANOX R03DX01 A01AD07 A A01 A01A A01AD MAGNESIUM CARBONATE A06AD01 A02AA01 A A02 A02A A02AA MAGNESIUM OXIDE A06AD02 A02AA02 A A02 A02A A02AA MAGNESIUM OXIDE A12CC10 A02AA02 A A02 A02A A02AA MAGNESIUM PEROXIDE A06AD03 A02AA03 A A02 A02A A02AA MAGNESIUM HYDROXIDE G04BX01 A02AA04 A A02 A02A A02AA CALCIUM CARBONATE A12AA04 A02AC01 A A02 A02A A02AC PAPAVERINE G04BE02 A03AD01 A A03 A03A A03AD ATROPINE S01FA01 A03BA01 A A03 A03B A03BA METHYLSCOPOLAMINE S01FA03 A03BB03 A A03 A03B A03BB SCOPOLAMINE N05CM05 A04AD01 A A04 A04A A04AD SCOPOLAMINE S01FA02 A04AD01 A A04 A04A A04AD BISACODYL A06AG02 A06AB02 A A06 A06A A06AB MAGNESIUM CARBONATE A02AA01 A06AD01 A A06 A06A A06AD MAGNESIUM OXIDE A02AA02 A06AD02 A A06 A06A A06AD MAGNESIUM OXIDE A12CC10 A06AD02 A A06 A06A A06AD MAGNESIUM PEROXIDE A02AA03 A06AD03 A A06 A06A A06AD MAGNESIUM SULFATE A12CC02 A06AD04 A A06 A06A A06AD MAGNESIUM SULFATE B05XA05 A06AD04 A A06 A06A A06AD MAGNESIUM SULFATE D11AX05 A06AD04 A A06 A06A A06AD Page 3 vr_meds_ex01_3b_0825s Coding Manual Supplement MAGNESIUM SULFATE V04CC02 A06AD04 A A06 A06A A06AD SODIUM SULFATE A12CA02 A06AD13 A A06 A06A A06AD MANNITOL B05BC01 A06AD16 A A06 A06A A06AD MANNITOL B05CX04 A06AD16 A A06 A06A A06AD SODIUM PHOSPHATE A06AG01 A06AD17 A A06 A06A A06AD SODIUM PHOSPHATE B05XA09 A06AD17 A A06 A06A A06AD SORBITOL A06AG07 A06AD18 A A06 A06A A06AD SORBITOL B05CX02 A06AD18 A A06 A06A A06AD SORBITOL V04CC01 A06AD18 A A06 A06A A06AD MAGNESIUM CITRATE A12CC04 A06AD19 A A06 A06A A06AD MAGNESIUM CITRATE B05CB03 A06AD19 A A06 A06A A06AD SODIUM PHOSPHATE A06AD17 A06AG01 A A06 A06A A06AG SODIUM PHOSPHATE B05XA09 A06AG01 A A06 A06A A06AG BISACODYL A06AB02 A06AG02 A A06 A06A A06AG GLYCEROL A06AX01 A06AG04 A A06 A06A A06AG SORBITOL A06AD18 A06AG07 A A06 A06A A06AG SORBITOL B05CX02 A06AG07 A A06 A06A A06AG SORBITOL V04CC01 A06AG07 A A06 A06A A06AG GLYCEROL A06AG04 A06AX01 A A06 A06A A06AX NEOMYCIN A01AB08 A07AA01 A A07 A07A A07AA NEOMYCIN B05CA09 A07AA01 A A07 A07A A07AA NEOMYCIN D06AX04 A07AA01 A A07 A07A A07AA NEOMYCIN J01GB05 A07AA01 A A07 A07A A07AA NEOMYCIN R02AB01 A07AA01 A A07 A07A A07AA NEOMYCIN S01AA03 A07AA01 A A07 A07A A07AA NEOMYCIN S02AA07 A07AA01 A A07 A07A A07AA NEOMYCIN S03AA01 A07AA01 A A07 A07A A07AA NYSTATIN D01AA01 A07AA02 A A07 A07A A07AA NYSTATIN G01AA01 A07AA02 A A07 A07A A07AA NATAMYCIN A01AB10 A07AA03 A A07 A07A A07AA NATAMYCIN D01AA02 A07AA03 A A07 A07A A07AA NATAMYCIN G01AA02 A07AA03 A A07 A07A A07AA NATAMYCIN S01AA10 A07AA03 A A07 A07A A07AA STREPTOMYCIN J01GA01 A07AA04 A A07 A07A A07AA POLYMYXIN B J01XB02 A07AA05 A A07 A07A A07AA POLYMYXIN B S01AA18 A07AA05 A A07 A07A A07AA POLYMYXIN B S02AA11 A07AA05 A A07 A07A A07AA Page 4 vr_meds_ex01_3b_0825s Coding Manual Supplement POLYMYXIN B S03AA03 A07AA05 A A07 A07A A07AA AMPHOTERICIN B A01AB04 A07AA07 A A07 A07A A07AA AMPHOTERICIN B G01AA03 A07AA07 A A07 A07A A07AA AMPHOTERICIN B J02AA01 A07AA07 A A07 A07A A07AA KANAMYCIN J01GB04 A07AA08 A A07 A07A A07AA KANAMYCIN S01AA24 A07AA08 A A07 A07A A07AA VANCOMYCIN J01XA01 A07AA09 A A07 A07A A07AA COLISTIN J01XB01 A07AA10 A A07 A07A A07AA RIFAXIMIN D06AX11 A07AA11 A A07 A07A A07AA MICONAZOLE A01AB09 A07AC01 A A07 A07A A07AC MICONAZOLE D01AC02 A07AC01 A A07 A07A A07AC MICONAZOLE G01AF04 A07AC01 A A07 A07A A07AC MICONAZOLE J02AB01 A07AC01 A A07 A07A A07AC MICONAZOLE S02AA13 A07AC01 A A07 A07A A07AC BROXYQUINOLINE G01AC06 A07AX01 A A07 A07A A07AX BROXYQUINOLINE P01AA01 A07AX01 A A07 A07A A07AX ACETARSOL G01AB01 A07AX02 A A07 A07A A07AX ACETARSOL P01CD02 A07AX02 A A07 A07A A07AX OPIUM N02AA02 A07DA02 A A07 A07D A07DA MORPHINE , COMBINATIONS N02AA51 A07DA52 A A07 A07D A07DA PREDNISOLONE C05AA04 A07EA01 A A07 A07E A07EA PREDNISOLONE D07AA03 A07EA01 A A07 A07E A07EA PREDNISOLONE D07XA02 A07EA01 A A07 A07E A07EA PREDNISOLONE H02AB06 A07EA01 A A07 A07E A07EA PREDNISOLONE R01AD02 A07EA01 A A07 A07E A07EA PREDNISOLONE S01BA04 A07EA01 A A07 A07E A07EA PREDNISOLONE S01CB02 A07EA01 A A07 A07E A07EA PREDNISOLONE S02BA03 A07EA01 A A07 A07E A07EA PREDNISOLONE S03BA02 A07EA01 A A07 A07E A07EA HYDROCORTISONE A01AC03 A07EA02 A A07 A07E A07EA HYDROCORTISONE C05AA01 A07EA02 A A07 A07E A07EA HYDROCORTISONE D07AA02 A07EA02 A A07 A07E A07EA HYDROCORTISONE D07XA01 A07EA02 A A07 A07E A07EA HYDROCORTISONE H02AB09 A07EA02 A A07 A07E A07EA HYDROCORTISONE S01BA02 A07EA02 A A07 A07E A07EA HYDROCORTISONE S01CB03 A07EA02 A A07 A07E A07EA HYDROCORTISONE S02BA01 A07EA02 A A07 A07E A07EA Page 5 vr_meds_ex01_3b_0825s Coding Manual Supplement PREDNISONE H02AB07 A07EA03 A A07 A07E A07EA BETAMETHASONE C05AA05 A07EA04 A A07 A07E A07EA BETAMETHASONE D07AC01 A07EA04 A A07 A07E A07EA BETAMETHASONE D07XC01 A07EA04 A A07 A07E A07EA BETAMETHASONE H02AB01 A07EA04 A A07 A07E A07EA BETAMETHASONE R01AD06 A07EA04 A A07 A07E A07EA BETAMETHASONE R03BA04 A07EA04 A A07 A07E A07EA BETAMETHASONE S01BA06 A07EA04 A A07 A07E A07EA BETAMETHASONE S01CB04 A07EA04 A A07 A07E A07EA BETAMETHASONE S02BA07 A07EA04 A A07 A07E A07EA TIXOCORTOL R01AD07 A07EA05 A A07 A07E A07EA BUDESONIDE D07AC09 A07EA06 A A07 A07E A07EA BUDESONIDE R01AD05 A07EA06 A A07 A07E A07EA BUDESONIDE R03BA02 A07EA06 A A07 A07E A07EA BECLOMETASONE D07AC15 A07EA07 A A07 A07E A07EA BECLOMETASONE R01AD01
Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of

    Antiseptics and Disinfectants for the Treatment Of

    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
  • Commission Decision of 8 February 2010 Concerning The

    Commission Decision of 8 February 2010 Concerning The

    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Survey and Risk Assessment of Chemical Substances in Deodorants

    Survey and Risk Assessment of Chemical Substances in Deodorants

    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
  • Composition for Rectal Administration Combined with an Oral Alpha-Lipoic

    Composition for Rectal Administration Combined with an Oral Alpha-Lipoic

    (19) & (11) EP 2 162 125 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/136 (2006.01) A61K 31/01 (2006.01) 19.10.2011 Bulletin 2011/42 A61P 1/00 (2006.01) A61K 45/06 (2006.01) A61K 31/56 (2006.01) A61K 31/573 (2006.01) (2006.01) (21) Application number: 08768441.1 A61K 31/606 (22) Date of filing: 13.06.2008 (86) International application number: PCT/US2008/007401 (87) International publication number: WO 2008/156671 (24.12.2008 Gazette 2008/52) (54) Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease Zusammensetzung zur rektalen Verabreichung kombiniert mit einer oralen Zusammentzung enthaltend alpha Liponsäure zur Behandlung von entzündlicher Darmerkrankung Composition pour l’administration rectale en combinaison avec une composition orale de l’ acide alpha- lipoique pour le traitment des maladies intestinales inflammatoires (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-B1- 0 671 168 WO-A2-02/089796 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT US-A- 4 657 900 US-A- 5 082 651 RO SE SI SK TR US-A- 5 378 470 (30) Priority: 13.06.2007 US 934505 P • MULDER CJ. ET AL.: ’Beclomethasone 06.02.2008 US 63745 P dipropionate (3mg) versus 5- aminosalicylic acid (2g) versus the combination of both (3mg/2g)as (43) Date of publication of application: retention enemas in active ulcerative proctitis’ 17.03.2010 Bulletin 2010/11 EUR.J.GASTROENTEROL HEPATOL vol.
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.